Effectiveness and safety of intravenous ferric carboxy maltose in anaemic women attending gynecological unit

Bharathi K. R., Pooja Bhat


Background: Anaemia is a significant problem worldwide, particularly in women. Several intravenous iron preparations are available for the treatment of anaemia. Some of them cause life-threatening anaphylactic reactions while others require multiple small infusions to prevent iron reactions. Ferric carboxy maltose (FCM), a non-dextran intravenous iron, is safe and effective option that can be administered as single high dose without serious adverse effects.

Methods: A prospective study was undertaken in the department of obstetrics and gynecology, Adichunchungiri institute of medical sciences, B G Nagara, from August 2020 to November 2021 in which 50 cases with iron deficiency anaemia were enrolled. IV FCM 1g was given. Change in the laboratory parameters such as haemoglobin (Hb), mean corpuscular value, serum ferritin levels over a 4 weeks period were observed.

Results: A significant increase in mean Hb from 8.14 to 11.71 g was observed in patients treated with FCM after 4 weeks of therapy. Majority belonged to age group of 21-30 years and moderate type of anaemia was most common. No serious drug reaction was reported.

Conclusions: IV FCM is safe and effective option for improving Hb in iron deficiency anaemia, in terms of restoring iron stores in short duration of time as well as patient compliance.


FCM, Iron deficiency anaemia, Parenteral therapy, Iron infusion

Full Text:



WHO. Fact sheet: Nutritional anemias. Report of a WHO scientific group. Geneva, World Health Organization, 1968. Available at: Accessed on 20 December 2021.

WHO. Fact sheet: Iron deficiency anemia assessment, prevention, and control: a guide for programme managers,2001. Available at: Accessed on 20 December 2021.

WHO. Fact sheet: Anemia in women & children, 2021. Available at: Accessed on 20 December 2021.

Government of India. National Family Health Survey 4- key indicators: 2015-2016. National Fam Health Surv. 2016;4:1-8.

Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci. 2014;19(2):164-74.

Gasche C, Lomer MCE, Cavill I, Weiss G. Iron, anemia, and inflammatory bowel diseases. Gut. 2004;53(8):190-7.

CDC. Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47(3):1-29.

Bentley ME, Griffiths PL. The burden of anemia among women in India. Eur J Clin Nutr. 2003;57(1):5260.

Kielmann K. Thresholds of morbidity among women in a peri-urban community of Maharashtra, India: conceptual and methodological issues. J Health Psychol. 2003;8(5):525-38.

Anouk P, Ganzevoort W. Safety and efficacy of ferric carboxymaltose in anemic pregnant women: A retrospective case control study. Obstet Gynecol Int. 2015;2015:728952.

Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103(5):1182-92.

Onken JE, Bregman DB, Harrington RA, Morris D, Acs P, Akright B. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014;54(2):306-15.

Mahey R, Kriplani A, Mogili KD, Bhatla N, Kachhawa G, Saxena R. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. Int J Gynaecol Obstet. 2016;133(1):43-8.

Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3):846-53.

VanWyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized controlled trial. Transfusion. 2009;49(12):2719-28.